NCT02521142

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of severe and irreversible visual loss and classified blindness in the elderly throughout Europe and the US. Among these patients, about 6%-8% are afflicted with the advanced stages of AMD, which are responsible for the most severe visual loss. There is now convincing evidence that vascular endothelial growth factor (VEGF) is a major trigger for the formation of pathological choroidal vessels, responsible for the development of the neovascular form of AMD. Today, the gold standard for vascular imaging of the retina and diagnosis of CNV is angiography using fluorescein (FLA) or indocyanine green (ICG), which involves injection of the dye into a vein of the arm. In the recent years tremendous enhancements in the field of optical coherence tomography have been achieved. These developments made it possible to visualize the retinal vasculature in a full depth manner without the application of an intravenous marker. The proposed study tests the hypothesis that visualisation of CNV lesion size with non-invasive OCT angiography is not inferior to FLA/ICG angiography in treatment naïve and previously treated AMD patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 3, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 13, 2015

Completed
3 months until next milestone

Study Start

First participant enrolled

November 1, 2015

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

January 17, 2023

Status Verified

January 1, 2023

Enrollment Period

8.1 years

First QC Date

August 3, 2015

Last Update Submit

January 13, 2023

Conditions

Keywords

OCT Angiography

Outcome Measures

Primary Outcomes (1)

  • Differences in visualization of lesion size between non-invasive OCT based optical angiography and FLA/ICG angiography in treatment-naïve and treated patients with CNV due to AMD.

    Participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days

Secondary Outcomes (2)

  • choroidal thickness as assessed with OCT

    participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days

  • peripapillarly bloodflow as assessed with Doppler OCT

    participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days

Study Arms (2)

AMD: treatment-naive

Other: Non-invasive OCT based optical angiographyOther: Oxymap T1Other: OCTOther: FLA/ICG angiography

AMD: active neovascular AMD

Other: Non-invasive OCT based optical angiographyOther: Oxymap T1Other: OCTOther: FLA/ICG angiography

Interventions

This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

AMD: active neovascular AMDAMD: treatment-naive

The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.

AMD: active neovascular AMDAMD: treatment-naive
OCTOTHER

non-invasive imaging of retinal and choroidal structures.

AMD: active neovascular AMDAMD: treatment-naive

Fluorescein Angiography and Indocianine Angiography

AMD: active neovascular AMDAMD: treatment-naive

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with CNV due to AMD both, treatment naive and active CNV being treated

You may not qualify if:

  • Any of the following will exclude a patient from the study:
  • Previous application of intravitreal drugs except anti-VEGF injections
  • Active intraocular inflammation
  • Presence of an intraocular disease except AMD and cataract

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, 1090, Austria

RECRUITING

Related Publications (1)

  • Told R, Reumueller A, Schranz M, Brugger J, Weigert G, Reiter GS, Sacu S, Schmidt-Erfurth U. OCTA Biomarker Search in Patients with nAMD: Influence of Retinal Fluid on Time-Dependent Biomarker Response. Curr Eye Res. 2023 Jun;48(6):600-604. doi: 10.1080/02713683.2023.2184318. Epub 2023 Mar 9.

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

August 3, 2015

First Posted

August 13, 2015

Study Start

November 1, 2015

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

January 17, 2023

Record last verified: 2023-01

Locations